Critically ill flu patients saved with artificial lung technology treatment

January 17, 2013

In recent weeks the intensive critical care units at University Health Network's Toronto General Hospital have used Extra Corporeal Lung Support (ECLS) to support five influenza (flu) patients in their recovery from severe respiratory problems.

ECLS systems are normally used at the hospital as a bridge to but increasingly, the hospital is using ECLS on patients where the usual breathing machines (ventilators) cannot support the patient whose lungs need time to rest and heal.

The ECLS systems are essentially artificial lungs that oxygenate the patient's blood outside the body, which gives lungs the chance to rest and heal. This method of oxygenation means that a is not used to help the patient breath and also means that the patient is not exposed to the possibility of further injury, which can happen to . The use of ECLS system requires expertise in its use to avoid other problems such as clots, bleeding problems and infections related to use of the device.

The lung is the only organ that, even when injured, is required to support the life of the patient while it is enduring the injury and trying to recover. The ventilators routinely used in this setting can actually add further injury to the lung on top of the original injury caused by the flu or . This is where ECLS can play an important role by taking over the job of the lung so that the lung has a chance to be treated, rest and recover.

"ECLS is an important part of our ability to bridge patients to lung transplantation and we have a great deal of experience in its use," said Dr. Shaf Keshavjee, who directs the ECLS Program as part of the Toronto Lung Transplant Program. Dr. Keshavjee is a thoracic surgeon and the Surgeon in Chief at University Health Network. "As the technology has improved over the years, we are now able to offer this life-saving therapy to the small percentage of patients with that get into severe trouble with .

This is part of our strategy to be prepared should we have a serious epidemic. The past few weeks have illustrated that our planning and training of our team has paid off. When several Ontario hospitals called us for help with their patients in serious lung failure, we were able to transfer those patients in and provide this life-saving therapy. All five patients survived to be weaned off the ECLS machines."

The use of ECLS requires insertion of a tube to remove blood from a large vein, which then has oxygen added to it and carbon dioxide removed. The blood is then pumped back into the patient through a second tube in another vein or artery. These patients are taken care of by a team of thoracic surgeons, intensivists, perfusionists and specially trained nurses in the Intensive Care Unit at TGH.

"Earlier this year, a patient arrived for urgent lung transplantation," said Dr. Eddy Fan, Intensivist and Medical Director of the ECLS Program at UHN's Toronto General Hospital. "After using ECLS, the patient's lungs healed themselves and we avoided a lung transplant. This is a remarkable outcome and our experience with is particularly rewarding for the lntensive Care Unit because we avoid the use of a ventilator which is very difficult for patients and can lead to further lung injury."

Explore further: New use of artificial lung device pioneered at University of Kentucky

Related Stories

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.